|Systematic (IUPAC) name|
|oral, intravenous, insufflation, sublingual, rectal|
|Biological half-life||24-36 h|
|Excretion||Urine, Test by specific gravity and bilirubin|
|ATC code||N02AC52 (WHO) N07, R05|
|Molar mass||309.445 g/mol[[Script error: No such module "String".]]|
|Script error: No such module "collapsible list".|
Methadone (also known as Symoron, Dolophine, Amidone, Methadose, Physeptone, Heptadon, Phy and many other names) is a synthetic opioid, used medically as an analgesic, antitussive and a maintenance anti-addictive for use in patients on opioids. It was developed in Germany in 1937. Although chemically unlike morphine or heroin, methadone also acts on the opioid receptors and thus produces many of the same effects. Methadone is also used in managing chronic pain owing to its long duration of action and very low cost. Methadone was introduced into the United States in 1947 by Eli Lilly and Company.
Methadone is useful in the treatment of opioid dependence. It has cross-tolerance with other opioids including heroin and morphine and a long duration of effect. Oral doses of methadone can stabilise patients by mitigating opioid withdrawal syndrome. Higher doses of methadone can block the euphoric effects of heroin, morphine, and similar drugs. As a result, properly dosed methadone patients can reduce or stop altogether their use of these substances.
Methadone is approved for different indications in different countries. Common is approval as an analgesic and approval for the treatment of opioid dependence. It is not intended to reduce the use of non-narcotic drugs such as cocaine, methamphetamine, or alcohol.
Today, a number of pharmaceutical companies produce and distribute methadone. The racemic hydrochloride is the only form available in most countries, such as the Netherlands, Belgium, France and in the United States, as of March 2008. The tartrate and other salts of the laevorotary form (levomethadone, with trade names including Polamidone and Heptadon) are available in Europe and elsewhere. These are possibly more potent and lack the cardiac effects such as lengthened QT interval caused by the dextrorotary form. The major producer remains Mallinckrodt, who sells bulk methadone to most of the producers of generic preparations and also distributes its own brand name product in the form of tablets, dispersible tablets and oral concentrate under the name Methadose in the United States.
- 1 History
- 2 Pharmacology
- 3 Withdrawal symptoms
- 4 Methadone maintenance treatment
- 5 Analgesic
- 6 Antitussive
- 7 Methadone as treatment for leukemia
- 8 Similar drugs
- 9 Notes
- 10 External links
Methadone was developed in 1939 Germany by scientists working for I.G. Farbenkonzern at the Farbwerke Hoechst (it is synthesised from 1,1-diphenylbutane-2-sulfonic acid and dimethylamino-2-chloropropane) who were looking for an synthetic opioid that could be created with readily available precursors, to solve Germany's opium shortage problem.
On September 11, 1941 Bockmühl and Ehrhart filed an application for a patent for a synthetic substance they called Hoechst 10820 or polamidon (a name still in regular use in Germany) and whose structure had only slight relation to morphine or the opiate alkaloids (Bockmühl and Ehrhart, 1949).
After the war, all German patents, trade names and research records were requisitioned and expropriated by the Allies. The records on the research work of the I.G. Farbenkonzern at the Farbwerke Hoechst were confiscated by the U.S. Department of Commerce Intelligence, investigated by a Technical Industrial Committee of the U.S. Department of State and then brought to the US.
The drug was given the trade name Dolophine from the Latin dolor meaning pain (Cf. Dipidolor for piritramide, Dolantin for pethidine, and the "-dol" ending common in many trade and chemical names for analgesics of all types in German, English, French, and other languages) and was not named either in honour of or personally by Adolf Hitler as explored in greater detail below.
It was only in 1947 that the drug was given the generic name “methadone” by the Council on Pharmacy and Chemistry of the American Medical Association (COUNCIL...1947). Since the patent rights of the I.G. Farbenkonzern and Farbwerke Hoechst were no longer protected each pharmaceutical company interested in the formula could buy the rights for commercial production of methadone for just one dollar (MOLL 1990). Commercial production was first introduced in 1947 by the U.S. company Eli-Lilly. Only then was methadone given the trade name Dolophine, derived from the Latin dolor (pain).
Methadone was introduced into the United States in 1947 by Eli Lilly and Company as an analgesic (they gave it the trade name Dolophine, which is now registered to Roxane Laboratories). Since then, it has been best known for its use in treating narcotic addiction. A great deal of anecdotal evidence was available "on the street" that methadone might prove effective in treating heroin withdrawal and it had even been used in some hospitals. It was not until studies performed at the Rockefeller University in New York City by Professor Vincent Dole, along with Marie Nyswander and Mary Jeanne Kreek, that methadone was systematically studied as a potential substitution therapy. Their studies introduced a sweeping change in the notion that drug addiction was not necessarily a simple character flaw, but rather a disorder to be treated in the same way as other diseases. To date, methadone maintenance therapy has been the most systematically studied and most successful, and most politically polarizing, of any pharmacotherapy for the treatment of drug addiction patients.
Methadone (as Dolophine) was first manufactured in the USA by Eli Lilly and Company Pharmacueticals, who first obtained FDA approval on August 14, 1947, for their Dolophine 5 mg and 10 mg Tablets. Mallinckrodt Pharmacueticals did not receive approval until December 15, 1947 to manufacture their bulk compounding powder. Mallinckrodt received approval for their branded generic, Methadose, on April 15, 1993 for their 5 mg and 10 mg Methadose Tablets. Mallinckrodt who also makes 5 mg, 10 mg and 40 mg generic tablets in addition to their branded generic Methadose received approval for their plain generic tablets on April 27, 2004.
The results of the early major studies showed methadone could effectively interrupt illicit opioid use and reduce the associated costs to society, findings which have been consistent with later research and backed up by modern knowledge of the psychological, social and pharmacological mechanisms of illicit opioid addiction.
Origin of Dolophine name
A persistent but untrue urban legend claims that the trade name "Dolophine" was coined in tribute to Adolf Hitler by its German creators, and it is sometimes even claimed that the drug was originally named "adolphine" or "adolophine" or "Dolphamine". Typically, the claim is still presented as fact by Church of Scientology literature and was repeated by actor and vocal Scientologist Tom Cruise in a 2005 Entertainment Weekly interview. However, as the magazine pointed out, this is not true: the name "Dolophine" was in fact created after the war by the American branch of Eli Lilly, and the pejorative term "adolphine" (never an actual name of the drug) appeared in the United States in the early 1970s.
Methadone acts by binding to the µ-opioid receptor, but also has some affinity for the NMDA ionotropic glutamate receptor. It is metabolized by the enzymes CYP3A4, CYP2B6 and CYP2D6, with great variability between individuals. Its main route of administration is oral. Adverse effects include hypoventilation, constipation and miosis, in addition to tolerance, dependence and withdrawal difficulties. The withdrawal period can be much more prolonged than with other opiates, spanning anywhere from two weeks to six months.
Mechanism of action
Methadone is a full µ-opioid agonist. Methadone also binds to the glutamatergic NMDA (N-methyl-D-aspartate) receptor, and thus acts as a receptor antagonist against glutamate. Glutamate is the primary excitatory neurotransmitter in the CNS. NMDA receptors have a very important role in modulating long term excitation and memory formation. NMDA antagonists such as dextromethorphan (DXM), ketamine (a dissociative anaesthetic, also M.O.A+.), tiletamine (a veterinary anaesthetic) and ibogaine (from the African tree Tabernanthe iboga, also M.O.A+.) are being studied for their role in decreasing the development of tolerance to opioids and as possible for eliminating addiction/tolerance/withdrawal, possibly by disrupting memory circuitry. Acting as an NMDA antagonist may be one mechanism by which methadone decreases craving for opioids and tolerance, and has been proposed as a possible mechanism for its distinguished efficacy regarding the treatment of neuropathic pain. Methadone also acted as a potent, noncompetitive α3β4 neuronal nicotinic acetylcholine receptor antagonist in rat receptors, expressed in human embryonic kidney cell lines.
Methadone has a slow metabolism and very high fat solubility, making it longer lasting than morphine-based drugs. Methadone has a typical elimination half-life of 15 to 60 hours with a mean of around 22. However, metabolism rates vary greatly between individuals, up to a factor of 100, ranging from as few as 4 hours to as many as 130 hours, or even 190 hours. This variability is apparently due to genetic variability in the production of the associated enzymes CYP3A4, CYP2B6 and CYP2D6. Many substances can also induce, inhibit or compete with these enzymes further affecting (sometimes dangerously) methadone half-life. A longer half life frequently allows for administration only once a day in Opioid detoxification and maintenance programs. Patients who metabolize methadone rapidly, on the other hand, may require twice daily dosing to obtain sufficient symptom alleviation while avoiding excessive peaks and troughs in their blood concentrations and associated effects. This can also allow lower total doses in some such patients. The analgesic activity is shorter than the pharmacological half-life; dosing for pain control usually requires multiple doses per day.
The toxic effects of an overdose can be treated with naloxone. Naloxone is preferred to the newer, longer acting antagonist naltrexone. Despite Methadone's much longer duration of action compared to either heroin and other shorter-acting agonists, and the need for repeat doses of the antagonist naloxone, it is still used for overdose therapy. As naltrexone has a longer half life, it is more difficult to titrate. If too large a dose of opioid antagonist is given to a dependent patient, it will result in withdrawal symptoms (possibly severe). When using naloxone, the naloxone will be quickly eliminated and the withdrawal will be short lived. Doses of naltrexone take longer to be eliminated from the patient's system.
Route of administration
The most common route of administration at a methadone clinic is in a racemic oral solution, though in Germany, only the R enantiomer (the L optical isomer) has traditionally been used, as it is responsible for most of the desired opioid effects. This is becoming less common due to the higher production costs.
Methadone is available in traditional pill, sublingual tablet, and two different formulations designed for the patient to drink. Drinkable forms include ready-to-dispense liquid, and "Disket" which is a tablet designed to disperse itself in water for oral administration, used in a similar fashion to Alka-Seltzer. The liquid form is the most common as it allows for smaller dose changes. Methadone is almost as effective when administered orally as by injection. In fact, injection of methadone may not result in a "rush" as with most stronger opioids, because its extraordinarily high volume of distribution causes it to diffuse into other tissues in the body, particularly fatty tissue; the peak concentration in the blood is achieved at roughly the same time, whether the drug is injected or ingested. When injecting Methadone, only pills have the least-dangerous cautions although it can easily cause collapsed veins, bruising, swelling and possibly other harmful effects. Methadone pills often contain talc that, when injected, produces a swarm of tiny solid particles in the blood, causing numerous minor blood clots. These particles cannot be filtered out before injection, and will accumulate in the body over time, especially in the lungs and eyes, producing various complications such as pulmonary hypertension, an irreversible and progressive disease. Methadose/Methadone should not be injected either. While it has been done in extremely diluted concentrations, instances of cardiac arrest have been reported as well as damaged veins from sugar and other ingredients (Sugar-Free syrups also should not be injected). Oral medication offers safety, simplicity and represents a step away from injection-based drug abuse in those recovering from addiction. U.S. federal regulations require the oral form in addiction treatment programs.
- Increased sweating, heat intolerance
- Chronic fatigue, sleepiness and exhaustion
- Constricted pupils
- Low blood pressure
- Cardiac arrhythmia
- Weight gain
- Stomach pains
- Dry mouth
- Difficulty urinating
- Swelling of the hands, arms, feet, and legs
- Mood changes
- Blurred vision
- Skin rash
Detection in biological fluids
Methadone and its major metabolite, EDDP, are often measured in urine as part of a drug abuse testing program, in plasma or serum to confirm a diagnosis of poisoning in hospitalized victims, or in whole blood to assist in a forensic investigation of a traffic or other criminal violation or a case of sudden death. Methadone usage history is considered in interpreting the results as a chronic user can develop tolerance to doses that would incapacitate an opioid-naive individual. Chronic users often have high methadone and EDDP baseline values.
In the United States, deaths linked to methadone more than quadrupled in five years. According to the U.S. National Center for Health Statistics, as well as a 2006 series in the Charleston (West Virginia) Gazette, medical examiners listed methadone as contributing to 3,849 deaths in 2004. That number was up from 790 in 1999. Approximately 82 percent of those deaths were listed as accidental, and most deaths involved combinations of methadone with other drugs (especially benzodiazepines).
Although deaths from methadone are on the rise, methadone-associated deaths are not being caused primarily by methadone intended for methadone treatment programs, according to a panel of experts convened by the Substance Abuse and Mental Health Services Administration, which released a report titled "Methadone-Associated Mortality, Report of a National Assessment". The consensus report concludes that "although the data remain incomplete, National Assessment meeting participants concurred that methadone tablets and/or diskettes distributed through channels other than opioid treatment programs most likely are the central factor in methadone-associated mortality."
In 2006, the U.S. Food and Drug Administration issued a caution about methadone, titled “Methadone Use for Pain Control May Result in Death.” The FDA also revised the drug's package insert. The change deleted previous information about the usual adult dosage. The Charleston Gazette reported, "The old language about the 'usual adult dose' was potentially deadly, according to pain specialists." 
Methadone treatment may impair driving ability. Drug abuse patients had significantly more involvement in serious crashes than non-abuse patients in a study by Queensland University. In the study of a group of 220 drug abuse patients, most of them poly-drug abusers, 17 were involved in crashes killing people, compared with a control group of other patients randomly selected having no involvement in fatal crashes. However, there have been multiple studies verifying the ability of methadone maintenance patients to drive.
Tolerance and dependence
As with other opioid medications, tolerance and dependence usually develop with repeated doses. Tolerance to the different physiological effects of methadone varies. Tolerance to analgesia usually occurs during the first few weeks of use; whereas with respiratory depression, sedation, and nausea it is seen within approximately 5–7 days. There is no tolerance formed to constipation produced by methadone or other opioids; however, effects may be less severe after time and can often be alleviated through increased intake of dietary fiber (fruits and vegetables, high-fiber cereals, etc.) or fiber supplements.
Physical symptoms
- Runny nose
- Severe Itching
- Aches and pains, often in the joints and/or legs
- Elevated pain sensitivity
- Elevated blood pressure
Cognitive symptoms
- Suicidal ideation
- Susceptibility to Cravings
- Adrenal exhaustion
- Adrenal fatigue
- Spontaneous orgasm
- Prolonged insomnia
- Auditory hallucinations
- Visual hallucinations
- Increased perception of odors (olfaction), real or imagined
- Marked decrease in sex drive
- Panic disorder
Withdrawal symptoms have shown to be up to twice as severe than those of morphine or heroin at equivalent doses but are significantly more prolonged; methadone withdrawal symptoms can last for several weeks or more. A general guideline is a 1:1 ratio for trouble free detox. Being on a constant dose of say 100ml for one year, can take 18–24 months for safe detoxification. At high maintenance doses, sudden cessation of therapy can result in withdrawal symptoms described as "the worst withdrawal imaginable," lasting from weeks to months.
There is a trend in the management of opiate addiction towards the reduction of a patient's methadone dosage to a point where they can be switched to buprenorphine or another opiate with an easier withdrawal profile. Methadone's long half-life and minimal side-effect profile makes it ideal for maintenance, but is not considered to be a desirable opiate to withdraw from when attempting to become completely opiate-free. However, when detoxing at a recommended rate (typically 1-2 mgs per week), withdrawal is either minimal or nonexistent, as the patient's body has time to adjust to each reduction in dose.
Methadone maintenance treatment
MMT (Methadone Maintenance Treatment), a form of opiate replacement therapy, reduces and/or eliminates the use of illicit opiates, the criminality associated with opiate use, and allows patients to improve their health and social productivity.  In addition, enrollment in methadone maintenance has the potential to reduce the transmission of infectious diseases associated with opiate injection, such as hepatitis and HIV. The principal effects of methadone maintenance are to relieve narcotic craving, suppress the abstinence syndrome, and block the euphoric effects associated with opiates. Methadone maintenance has been found to be medically safe and non-sedating. It is also indicated for pregnant women addicted to opiates.
In Russia, methadone treatment is illegal. Health officials there are not convinced of the treatment's efficacy. Instead, doctors encourage immediate abstinence from drug use, rather than the gradual process that methadone substitution therapy entails. Patients are often given sedatives and painkillers to cope with withdrawal symptoms.
A majority of patients require 80–120 mg/d of methadone, or more, to achieve these effects and require treatment for an indefinite period of time, since methadone maintenance is a corrective but not a curative treatment for opiate addiction. Lower doses are sometimes not as effective, or do not provide an equivalent blockade effect as higher dosages can. Some patients will be prescribed as much as 500 mg of methadone a day; though a dose as low as 10 mg can prove fatal in an opiate naive individual.
In the United States clinics typically start patients at a low dose, generally only starting patients on methadone when they are in withdrawal and providing a small test dose, after which the patients are observed for possible adverse effects. Assuming there are no complications, the remaining portion of the first day's dose is then given. After this the doses are titrated until they reach either a clinically sufficient level that prevents withdrawal, cravings and possible continued use of illicit opioids, or until they reach a maximum dose set by clinic policy. For example, a clinic may start patients at 30 mg and raise the dosage 5 mg a day until the patient reports feeling comfortable (e.g. free of withdrawal symptoms). Alternatively, the clinic may stop dosage at 80 mg, then allow the patient to move up by 5 mg or 10 mg every 2 or 3 days, until they are free from withdrawal symptoms and intense cravings. Once stabilized, patients may require periodic dose adjustments as their clinical or subjective tolerance changes.
The most common and traditional dosing regimens, however, tend to fall far short of providing optimum or even sufficient results for a number of patients. This is due to the ceilings many clinics place on dose levels.
Until recently a 100-mg/d dose was regarded as a 'glass ceiling,' rarely to be penetrated. In practice much lower thresholds were maintained even though the optimal dose varies greatly between patients, often quite higher than this and with no inherent threshold in the possible dose, as the toxic dose for patients with very high tolerance can exceed this ten-fold or more. The blood concentrations of patients on an equivalent dose (when adjusted for body weight) can vary as much as 17-fold, or up to 41-fold when influenced by other medications, leading to a vast range of potentially required doses.
In the United States, federal law was changed in 2001 to eliminate some restrictions imposed on patients dosed on more than 100 mg per day.
While there is much debate generally over treatment schedules and duration, patients can often obtain indefinite treatment at their methadone clinic—lasting as long as the patient requires it. Many factors determine the treatment schedule, including specific clinic policies which sometimes require patients to taper regardless of their desire to do so. In general, methadone maintenance is seen as ongoing symptom management rather than a curative treatment. This has buttressed the arguments of those who view methadone as just another prescription drug taken for a long-term, chronic condition.
A patient's dose of methadone may be reduced by a slow taper with minimal discomfort. Patients undergoing MMT at a clinic where they are given a daily dose have the opportunity to attempt a dose reduction and return to the previous dose if they are feeling discomfort. Policies on dose reduction vary from clinic to clinic, from a focus on eventually tapering the patient off of methadone altogether to a focus on maintaining a high dose to prevent the use of illicit opioids. Many methadone clinics will adjust doses upon personal evaluation of the correct care for the individual patient. A higher methadone dose may be considered preferable by a clinic treating patients addicted to illicit opioids, in order to discourage the use of illegal opioids. This can be due to the large increase in tolerance, a chemical blocking effect caused by methadone above certain doses, or by filling a psychological or physical need that illicit opioids were previously being used for.
To minimize or prevent patient discomfort, the methadone dose must be decreased slowly. Typical reduction rates vary and should be adjusted based on patient response.
Frequently this adjustment is monitored on a daily basis. Most of the literature focuses on methadone maintenance patients visiting clinics daily, focused on heroin substitution. Chronic pain patients wishing to decrease their methadone dose must follow similar titration regimens. However their doctor may substitute alternative opioids during this period, altering what rate is compatible with patient comfort when compared with complete detoxification.
Methadone tapering works best when done as a slow and gradual reduction in dose, dropping 5 mg every three to 14 days. At this rate there should be very few, if any, physical symptoms during the taper.
Once the dose is lowered to around 20 mg, the tapering may be slowed down to an even more gradual reduction, to reduce or eliminate any symptoms.
Nowadays, most methadone providers will allow you to choose the rate at which your dose is reduced.
Aegis Medical Systems Tapering Off of Methadone Maintenance: Evidence-Based Guidelines 
recommends regular evaluation of the patient's withdrawal symptoms, counseling where needed, and a generally slow rate, noting:
Dr. J. Thomas Payte, a highly experienced clinician and researcher, has suggested that a 7-10 day period between dose decreases should be adequate time to adjust before the next drop.
Clinical experience reminds us of an important rule in tapering, “THE SLOWER, THE BETTER,”
The College of Pharmacists of British Columbia discusses more specific rates on page 19 of a slide presentation:
- Greater detox. completion rates with greater time spent in MMT & slower taper.
- Taper rate
- < 10 mg or 10% per week.
- Slower taper below 20-30 mg.
Mallinckrodt, the primary manufacturer of methadone in the US, has guidelines  that include
For Medically Supervised Withdrawal After a Period of Maintenance Treatment There is considerable variability in the appropriate rate of methadone taper in patients choosing medically supervised withdrawal from methadone treatment. It is generally suggested that dose reductions should be less than 10% of the established tolerance or maintenance dose, and that 10 to 14-day intervals should elapse between dose reductions. Patients should be apprised of the high risk of relapse to illicit drug use associated with discontinuation of methadone maintenance treatment.
Visits to clinics
Methadone has traditionally been provided to people who are opiate dependent in a highly regulated methadone clinic, generally associated with an outpatient department of a hospital, though this varies country by country. For example in Australia, Methadone maintenance treatment (MMT) is delivered by private pharmacies for a nominal fee to the client (regardless of the fact it is free as it is subsidised by the Federal government). This nominal fee covers the costs of providing the service, such as purchase and maintenance of supplies and equipment like dosing cups and precision measuring devices, supply costs involved in transporting a highly regulated drug from supplier to the pharmacy, extensive record-keeping as per government requirements, and compensation to the pharmacy staff for the time involved in preparing for and dosing a client (none of which are funded by the Federal government).
In many Western countries, new patients are required to visit the clinic daily so that they may be observed taking their dose by the dispensing nurse, but may be allowed to leave the clinic with increasing supplies of "take home doses" or "carries" after several months of adherence to the clinic's regulations, including consistent negative drug-screen results. The way that MMT is delivered in some countries create barriers to scaling up access to the treatment. For example, in Australia, people who are on MMT are dosed in a designated area in front of other pharmacy customers. This can inhibit people's willingness to access treatment due to a lack of confidentiality and anonymity. In most well-designed pharmacies in Australia, however, dosing occurs in a discreet location away from other customers, and may even take place in a room specially designed for this purpose. In some countries or regions, law stipulates that clinics may provide at most one week's worth of methadone (up to 30 days in the USA but states may allow as few as three), except for patients unable to visit the clinic without undue hardship due to a medical disability or infrequent exceptions made for necessary travel to areas without clinics, and this level is only reached after a few years of proper results. A lot of patients report that this type of treatment is the only long term treatment option that has ever continued to be effective for them. A lot of mental issues that come from discontinuing the use of all types of opiates do not cease for years or more. The methadone programs, if correctly monitored, can help the patient get back to their life and be able to function without the constant cravings and insomnia reported after quitting opaites. Methadone can provide a method of stable treatment of the symptoms associated with withdrawal and mental anguish, and, with a proper slow taper, can be discontinued after the patient feels he or she is ready. Usually after 1 or 2 years or more, which gives the addict time to get away from old habit and/or triggers.
In the U.S., MMT patients generally receive psycho-social support (i.e. "counseling"), which is provided on site. Although laws vary, this is required in many states and countries regardless of whether a person needs or wants to engage in that kind of intervention (for example, recent changes in Taiwan). Patients are often required to attend 10 hours or more of therapy per week, having their daily dose withheld (thereby inducing withdrawal) for failure to comply. Methadone maintenance is rarely covered by private insurance and patients are encouraged to enroll in public welfare programs or face upwards of $500 USD per month. Since a supervised dose costs more than a take-home dose, and the risk of diversion, clinics are often reluctant to provide take-home privileges.
In the Netherlands, MMT is fully covered under basic health insurance. Since every person over the age of 18 is obliged to have health insurance, everyone is covered. For opioid dependent homeless people, treatment costs are covered by government subsidies.
In Germany, MMT is fully covered by all public and private insurance. The annual cost per patient is less than 3000 euros, while Heroin assisted treatment costs up to 10,000 euros per year.
Methadone clinics in the U.S. charge anywhere from $50–300 per week, which may be covered by private insurance or Medicaid. "Cash-only" clinics do not accept insurance, requiring patients to pay up front and then seek reimbursement from their insurance carrier.
In recent years, methadone has gained popularity among physicians for the treatment of other medical problems, such as an analgesic in chronic pain. The increased usage comes as doctors search for an opioid drug that can be dosed less frequently than shorter-acting drugs like morphine or hydrocodone. Another factor in the increased usage is the low cost of methadone.                 
While the cost for pain patients varies based on many factors, leading to few specifics in the literature, one source states:
however, in some cases monthly costs to patients for oral methadone can be morethan 30-fold less than equianalgesic doses of other generic or brand-name opioid analgesics.
A week's supply will typically have a retail cost of $50–$70 in the United States, compared to hundreds of dollars for alternative opioids. Methadone, with its long half-life (and thus long duration of effect) and good oral bioavailability, is a common second-choice drug for pain that does not respond to weaker agonists. A major drawback is that unlike OxyContin (oxycodone continuous release), methadone is not technologically engineered for sustained release of the drug so blood concentrations will fluctuate greatly between dosing. This problem is overcome to a great extent by the practice of dosing methadone two or three times a day in pain patients. Some physicians also choose methadone for treating chronic pain in patients who are thought to have a propensity for addiction, because it causes less of an intoxicated or euphoric "high". The effect is of morphine-equivalent origin.
On November 29, 2006, the U.S. Food and Drug Administration issued a Public Health Advisory about methadone titled "Methadone Use for Pain Control May Result in Death and Life-Threatening Changes in Breathing and Heart Beat." The advisory went on to say that "the FDA has received reports of death and life-threatening side effects in patients taking methadone. These deaths and life-threatening side effects have occurred in patients newly starting methadone for pain control and in patients who have switched to methadone after being treated for pain with other strong narcotic pain relievers. Methadone can cause slow or shallow breathing and dangerous changes in heart beat that may not be felt by the patient." The advisory urged that physicians use caution when prescribing methadone to patients who are not used to the drug, and that patients take the drug exactly as directed. As with any strong medication that can be fatal in large doses, methadone must be taken properly and with due care. Otherwise, the accumulation of methadone could potentially reach a level of toxicity if the dose is too high or if the user's metabolism of the drug is slow. In such a situation, a patient who fared fine after the first few doses could reach high levels of the drug in his body without ever taking more than was prescribed. For this reason, it is reasonable to make sure that patients who do not have a tolerance to opiates be prescribed methadone in initially small doses, and that when sent home, patients and their families are made very aware of the symptoms characteristic of opiate overdose. Also, there is some evidence that methadone and other opioids may cause cardiac conduction problems (prolonged QTc interval) although there are few documented cases of fatalities resulting from this side effect with methadone.
In an effort to turn the tide on reported increases in methadone-related adverse events, the DEA announced in a recent advisory that manufacturers of methadone hydrochloride 40-mg tablets have agreed to restrict their distribution of that particular formulation of the drug.
As of 1. January 2008, manufacturers will ship the methadone hydrochloride 40-mg formulation only to hospitals and facilities that have been authorized for detoxification and maintenance treatment of patients with opioid addiction. In addition, manufacturers of the drug will instruct their wholesale distributors to stop supplying the formulation to any facility that doesn't meet the criteria.
The DEA advisory stresses that the 40-mg formulation of methadone hydrochloride is indicated only for the detoxification and maintenance treatment of opioid-addicted patients and is not FDA-approved for use in pain management.
Federal law does not restrict the prescribing, dispensing or administration of methadone for the treatment of pain, and the 5-mg and 10-mg methadone formulations will continue to be available as a tool that family physicians can use to treat patients for pain. Despite the FDA directive, many doctors continue to prescribe Methadone as a pain killer, but only to patients which have shown to be responsible in their use of previous pain killers. One reason for use of Methadone is its advantages for opioid rotation.
Patients with long-term pain will sometimes have to perform so-called opioid rotation. By this is meant switching from one opioid to another, usually at intervals of between a few weeks and, more commonly, several months. Opioid rotation is good because switching to another opioid gives lower dose, and because of this less side effects, to achieve the desired effect. Then, with the new opioid, tolerance grows, higher doses are needed, and toxicity in relation to analgesic effects increase. So then it is time rotate again to another opioid. Such opioid rotation is standard practice for managing patients with tolerance development problems. Usually, when doing opioid rotation, one cannot go down to a completely naive dose, because there is cross-tolerance, so some of the high tolerance is brought over to the new opioid. However, Methadone has much lower cross-tolerance, when switching to it from other opioids, than other opioids. This means that Methadone can start at a low dose, and the time for the next switch will be longer.
All opioids have as a major side effect tiredness, which can go to an almost half-awake stage (=sedation, in medical terms). Many patients report that Methadone's sedation effect is often less pronounced than with other opioids and cite this as a major argument for preferring Methadone as an analgesic.
Methadone linctus, which is about one-third the concentration of the liquid methadone used for opioid maintenance, is used where available and approved for such use as a cough syrup for violent coughing. Narcotic cough suppressants are very useful against dry, unproductive coughing, especially that which persists after an illness has otherwise resolved and/or is a manifestation of recurring bronchitis, causes pain in the chest, and/or prevents the patient from sleeping. These drugs work directly on the coughing centre in the brain, and several branches of the opioid family contain effective cough suppressants.
Natural and semi-synthetic opiates with antitussive effects include codeine, ethylmorphine (also known as dionine or codethyline), dihydrocodeine, benzylmorphine, laudanum, dihydroisocodeine, nicocodeine, nicodicodeine, hydrocodone, hydromorphone, acetyldihydrocodeine, thebacon, diamorphine (heroin), acetylmorphone, noscapine and pholcodine and others. Amongst other synthetics are dimemorfan and dextromethorphan in the morphinan group, tipepidine of the thiambutenes, and other drugs of the open-chain (methadone) type with antitussive efficacy include levomethadone, normethadone and levopropoxyphene. There is also the newer synthetic Zipeprol, classified as 'Other'(not available in the U.S. or CA).
Methadone as treatment for leukemia
Researchers in Germany have discovered that methadone has surprising killing power against leukemia cells, including treatment-resistant forms of the cancer. Their laboratory study, published in the 1 August 2008 issue of Cancer Research, a journal of the American Association for Cancer Research, suggests that methadone holds promise as a new therapy for leukemia, especially in patients whose cancer no longer responds to chemotherapy and radiation.
There are two methadone isomers. The racemic mixture is more common as it is cheaper to produce. The laevorotary isomer, which is isolated by several recrystalisations from racemic methadone, is more expensive to produce. It is stronger than the racemic mixture and is marketed especially in continental Europe as an analgesic under the trade names Levo-Polamidone, Polamidone, Heptanone, Heptadone, Heptadon and others. It is used as the hydrochloride salt almost exclusively with some uncommon pharmaceuticals and research subjects consisting of the tartrate.
The closest chemical relative of methadone in clinical use is levo-α-acetylmethadol or LAAM. It has a longer duration of action (from 48 to 72 hours), permitting a reduction in frequency of use. In 1994, it was approved as a narcotic addiction treatment. In the Netherlands, like methadone and all other strong opioids, LAAM is a List I drug of the Opium Law, and in Schedule II of the United States Controlled Substances Act. LAAM has since been removed from the US and European markets due to reports of rare cardiac side effects.
Other drugs which are not structurally related to methadone are also used in maintenance treatment, particularly Subutex (buprenorphine) and Suboxone (buprenorphine combined with naloxone). In the NL, Switzerland, the UK and a few other European countries, however, not only buprenorphine and oral methadone but also injectable methadone and pharmaceutical diamorphine (heroin) or other opioids may be used for outpatient maintenance treatment of opiate addiction, and treatment is generally provided in much less heavily regulated environments than in the United States. In the United Kingdom, diamorhpine is used extremely selectively and is not available on prescription to addicts; except in specialist trials which involved no more than 300 participants. A study from Austria indicated that oral morphine (in the form of MS-Contin) provides better results than oral methadone, and studies of heroin maintenance have indicated that a low background dose of methadone combined with heroin maintenance may significantly improve outcomes for less-responsive patients. Other opiates such as dihydrocodeine in both extended-release and immediate-release form are also sometimes used for maintenance treatment as an alternative to methadone or buprenorphine in some European countries.
Another close relative of methadone is dextropropoxyphene, first marketed in 1957 under the trade name of Darvon. Oral analgesic potency is one-half to one-third that of codeine, with 65 mg approximately equivalent to about 600 mg of aspirin. Dextropropoxyphene is prescribed for relief of mild to moderate pain. Bulk dextropropoxyphene is in Schedule II of the United States Controlled Substances Act, while preparations containing it are in Schedule IV. More than 100 tons of dextropropoxyphene are produced in the United States annually, and more than 25 million prescriptions are written for the products. Since dextropropoxyphene produces relatively modest pain relief compared to other opioids but still produces severe respiratory depression at high doses, it is particularly dangerous when abused, as drug users may take dangerously high doses in an attempt to achieve narcotic effects. This narcotic is among the top 10 drugs reported by medical examiners in recreational drug use deaths. However, dextropropoxyphene is still prescribed for the short term relief of opiate withdrawal symptoms, particularly when the aim of treatment is to smooth detoxification to a drug free state rather than a switch to maintenance treatment.
Other analogues of methadone which are still in clinical use are dipipanone (Diconal) and dextromoramide (Palfium) which are shorter-lasting but considerably more effective as analgesics. In the 1980s and beginning of the 1990s, before pharmaceutical grade IV heroin treatment became available to heroin addicts, as either single drug replacement for street heroin, or to be used alongside prescribed methadone, oral dextromoramide was prescribed to heroin addicts instead, because even when taken orally it still produces a strong, so called "rush", without the need of IV administration and any of the risks involved with it. These drugs have a high potential for abuse and dependence and were notorious for being widely abused and sought after by drug addicts in the 1970s. They are still rarely used for the relief of severe pain in the treatment of terminal cancer or other serious medical conditions.
Cite error: Invalid
parameter "group" is allowed only.
<references />, or
<references group="..." />
- ONDCP Fact Sheet
- Clinic Locator, United States
- DHHS, Centers for Disease Control and Prevention (CDC)
- Methadone Support Org - Pregnancy, Methadone Anonymous (MA)
- TAPERING OFF OF METHADONE MAINTENANCE: EVIDENCE-BASED GUIDELINES
- Methadone Package Insert
- BEST PRACTICES: Methadone Maintenance Treatment
- U.S. National Library of Medicine: Drug Information Portal - Methadone
bs:Metadon ca:Metadona cs:Metadon da:Metadon de:Methadon et:Metadoon es:Metadona eo:Metadono eu:Metadona fa:متادون fr:Méthadone ga:Meatadón gl:Metadona it:Metadone he:מתאדון hu:Metadon nl:Methadon ja:メタドン no:Metadon pl:Metadon pt:Metadona ru:Метадон simple:Methadone sk:Metadón sl:Metadon sr:Метадон sh:Metadon fi:Metadoni sv:Metadon th:เมทาโดน tr:Methadon uk:Метадонzh:美沙酮
- M. Bockmuhl, Über eine neue Klasse von analgetisch wirkenden Verbindungen Ann. Chem. 561, 52 (1948)
- Tom Responds, Entertainment Weekly, May 11, 2005
- "Methadone Briefing". Archived from the original on 2003-11-20. Retrieved 2007-07-09.
- Indro-Online.de (PDF format)
- "Blockade of Rat α3β4 Nicotinic Receptor Function by Methadone, Its Metabolites, and Structural Analogs — JPET".
- Kell MJ (1994). "Utilization of plasma and urine methadone concentrations to optimize treatment in maintenance clinics: I. Measurement techniques for a clinical setting". Journal of addictive diseases: the official journal of the ASAM, American Society of Addiction Medicine. 13 (1): 5–26. PMID 8018740.
- Eap CB, DeglonJ-J, Boumann P. (1999). "Pharmacokinetics and pharmacogenetics of methadone: Clinical relevance". Heroin Addiction and Related Clinical Problems: the official journal of EUROPAD, European Opiate Addiction Treatment Association. 1 (1): 19–34.
- Eap CB, Buclin T, Baumann P (2002). "Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence". Clinical pharmacokinetics. 41 (14): 1153–93. PMID 12405865.
- Manfredonia, John (2005-03-18). "Prescribing Methadone for Pain Management in End-of-Life Care". JAOA The Journal of the American Osteopathic Association. Retrieved 2007-01-29.
- Public Health Issue: Methadone Maintenance Therapy RICHARD SADOVSKY, M.D. - Anderson IB, Kearney TE. Use of methadone. West J Med January 2000;172:43-6.
- "Methadone Hydrochloride Tablets, USP" (PDF). VistaPharm.
- "Talc retinopathy". Can J Ophthalmol.
- "Talc lung in a drug abuser". Springer London.
- "Pulmonary Hypertension and Risk of Death in Cardiomyopathy". Circulation.
- "Improving survival in pulmonary arterial hypertension". European Respiratory Journal.
- Nicholas Lintzeris, Michael Lenne, Alison Ritter (1999). "Methadone injecting in Australia: A Tale of Two Cities". Addiction. 94 (8): 1175–1178. doi:10.1046/j.1360-0443.1999.94811757.x.
- Code of Federal Regulations, Title 42, Sec 8.
- "Dolophine Drug Description". RxList.
- "Methadone". MedlinePlus. Archived from the original on 2008-02-27.
- "Methadone". Drugs.com.
- "Methadone". MedicineNet.
- R. Baselt, Disposition of Toxic Drugs and Chemicals in Man, 8th edition, Biomedical Publications, Foster City, CA, 2008, pp. 941-945.
- "Increases in Methadone-Related Deaths:1999-2004".
- "The Killer Cure" The Charleston Gazette 2006
- "Methadone-Associated Mortality, Report of a National Assessment".
-  Charleston Gazette, "New warning issued on methadone", Nov. 28, 2006
- Giacomuzzi SM, Ertl M, Vigl A, et al. 2005. Driving capacity of patients treated with methadone and slow-release oral morphine. Addiction 100 (7): 1027.
- Reece AS. 2008. Experience of road and other trauma by the opiate dependent patient: a survey report. Substance Abuse Treatment, Prevention, and Policy 3: 10.
- "Methadone, Methadone Addiction & Methadone Side Effects By Narconon Arrowhead & Heroin Addiction". Retrieved 31 October 2008.
- Joseph H, Stancliff S, Langrod J (2000). "Methadone maintenance treatment (MMT): a review of historical and clinical issues". Mt. Sinai J. Med. 67 (5-6): 347–64. PMID 11064485.
- Connock M, Juarez-Garcia A, Jowett S; et al. (2007). "Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation". Health technology assessment (Winchester, England). 11 (9): 1–171, iii–iv. PMID 17313907.
- M Schwirtz. "Russia Scorns Methadone for Heroin Addiction." The New York Times. July 22, 2008.
- Donny EC, Brasser SM, Bigelow GE, Stitzer ML, Walsh SL (2005). "Methadone doses of 100 mg or greater are more effective than lower doses at suppressing heroin self-administration in opioid-dependent volunteers". Addiction. 100 (10): 1496–509. doi:10.1111/j.1360-0443.2005.01232.x. PMID 16185211.
- Latowsky M (2006). "Methadone death, dosage and torsade de pointes: risk-benefit policy implications". Journal of psychoactive drugs. 38 (4): 513–9. PMID 17373567.
- Leavitt SB, Shinderman M, Maxwell S, Eap CB, Paris P (2000). "When "Enough" Is Not Enough: New Perspectives on Optimal Methadone Maintenance Dose". Mount Sinai Journal of Medicine. 67 (5&6): 404–411.
- Faggiano F, Vigna-Taglianti F, Versino E, Lemma P (2003). "Methadone maintenance at different dosages for opioid dependence". Cochrane database of systematic reviews (Online) (3): CD002208. doi:10.1002/14651858.CD002208. PMID 12917925.
- "Centre for Addiction and Mental Health". The Centre for Addiction and Mental Health.
- "Tapering Off of Methadone Maintenance: Evidence-Based Guidelines" (PDF). "Aegis Medical Systems".
- "Methadone Maintenance Program Overview" (PDF). The College Of Pharmacists Of British Columbia. "The College Of BC Pharmacists".
- "METHADONE HYDROCHLORIDE TABLETS USP Prescribing Information" (PDF). Mallinckrodt.
- "Best Practices Methadone Maintenance Treatment" (PDF). Office of Canada’s Drug Strategy Health Canada.
- "Methadone Maintenance Treatment Translating Research Into Policy" (PDF). Canadian Department Of Health And Human Services.
- "Methadone Maintenance Treatment". Drug Policy Alliance Lindesmith Library.
- "Methadone Research Web Guide". NIDA.
- Leppert, W. (2009). "The role of methadone in cancer pain treatment--a review". International journal of clinical practice. 63 (7): 1095–1109. doi:10.1111/j.1742-1241.2008.01990.x. PMID 19570126.
- Shelton, BW; Deynes-Romero, J; Tofani-Montalvo, M; Ramírez-Rivera, J; Jaumne-Anselmi, F (2008). "Methadone: an effective alternative to morphine for pain relief in cancer patients". Boletin de la Asociacion Medica de Puerto Rico. 100 (3): 7–10. PMID 19227708.
- Yennurajalingam, S.; Peuckmann, V.; Bruera, E. (2004). "Recent developments in cancer pain assessment and management". Supportive cancer therapy. 1 (2): 97–110. doi:10.3816/SCT.2004.n.003. PMID 18628186.
- Mercadante, S.; Porzio, G.; Ferrera, P.; Fulfaro, F.; Aielli, F.; Verna, L.; Villari, P.; Ficorella, C.; Gebbia, V. (2008). "Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management". European journal of pain (London, England). 12 (8): 1040–1046. doi:10.1016/j.ejpain.2008.01.013. PMID 18353696.
- Swegle, J.; Wensel, D. (2008). "The safety of methadone hydrochloride". Expert opinion on drug safety. 7 (1): 5–8. doi:10.1517/147403126.96.36.199. PMID 18171310.
- Lynch, ME (2005). "A review of the use of methadone for the treatment of chronic noncancer pain". Pain research & management : the journal of the Canadian Pain Society = journal de la societe canadienne pour le traitement de la douleur. 10 (3): 133–44. PMID 16175249.
- Juver, JP; Figueiredo, NV; Barrucand, L; Tostes Mde, A (2005). "Methadone to treat non-oncologic neuropathic pain. Case reports". Revista brasileira de anestesiologia. 55 (4): 450–9. PMID 19468634.
- Toombs, JD; Kral, LA (2005). "Methadone treatment for pain states". American family physician. 71 (7): 1353–8. PMID 15832538.
- Ribeiro, S; Schmidt, AP; Schmidt, SR (2002). "Opioids for treating non malignant chronic pain: the role of methadone". Revista brasileira de anestesiologia. 52 (5): 644–51. PMID 19475235.
- Ripamonti, C; Bianchi, M (2002). "The use of methadone for cancer pain". Hematology/oncology clinics of North America. 16 (3): 543–55. doi:10.1016/S0889-8588(02)00017-5. PMID 12170567.
- Rischitelli, DG; Karbowicz, SH (2002). "Safety and efficacy of controlled-release oxycodone: a systematic literature review". Pharmacotherapy. 22 (7): 898–904. doi:10.1592/phco.22.11.898.33628. PMID 12126222.
- Bruera, E.; Sweeney, C. (2002). "Methadone use in cancer patients with pain: a review". Journal of palliative medicine. 5 (1): 127–138. doi:10.1089/10966210252785097. PMID 11839235.
- Hagen, NA; Wasylenko, E (1999). "Methadone: outpatient titration and monitoring strategies in cancer patients". Journal of pain and symptom management. 18 (5): 369–75. doi:10.1016/S0885-3924(99)00083-4. PMID 10584461.
- Bruera, E; Neumann, CM (1999). "Role of methadone in the management of pain in cancer patients". Oncology (Williston Park, N.Y.). 13 (9): 1275–82; discussion 1285–8, 1291. PMID 10509323.
- Gardner-Nix, JS (1996). "Oral methadone for managing chronic nonmalignant pain". Journal of pain and symptom management. 11 (5): 321–8. doi:10.1016/0885-3924(95)00191-3. PMID 8636630.
- Watanabe, S; Belzile, M; Kuehn, N; Hanson, J; Bruera, E (1996). "Capsules and suppositories of methadone for patients on high-dose opioids for cancer pain: clinical and economic considerations". Cancer treatment reviews. 22 Suppl A: 131–6. PMID 8625339.
- Thomas, Z.; Bruera, E. (1995). "Use of methadone in a highly tolerant patient receiving parenteral hydromorphone". Journal of Pain and Symptom Management. 10 (4): 315. doi:10.1016/0885-3924(95)00011-M. PMID 7541438.
- "Oral Methadone Dosing For Pain" (PDF). Pain Treatment Topics.
- "2006 Safety Alerts for Drugs, Biologics, Medical Devices, and Dietary Supplements". MedWatch. Food and Drug Administration.
- Maremmani I, Pacini M, Cesaroni C, Lovrecic M, Perugi G, Tagliamonte A (2005). "QTc interval prolongation in patients on long-term methadone maintenance therapy". European addiction research. 11 (1): 44–9. doi:10.1159/000081416. PMID 15608471.
- "Opioid rotation for toxicity reduction in terminal cancer patients". Journal of Pain and Symptom Management. Volume 10, Issue 5, July 1995, Pages 378-384.
- "Individualized use of methadone and opioid rotation in the comprehensive management of cancer pain associated with poor prognostic indicators". <pain. Elsevier, Amsterdam, PAYS-BAS, 1996, vol. 67, no1, pp. 115-119 (30 ref.).
- "Pitfalls of opioid rotation: substituting another opioid for methadone in patients with cancer pain" (PDF). <pain. 96 (2002) 325–328).
- Claudia Friesen, Mareike Roscher, Andreas Alt and Erich Miltner (2008). "Methadone, Commonly Used as Maintenance Medication for Outpatient Treatment of Opioid Dependence, Kills Leukemia Cells and Overcomes Chemoresistance". Cancer Research. 68 (15): 6059–6064. doi:10.1158/0008-5472.CAN-08-1227. PMID 18676827.
- Michels II, Stover H, Gerlach R. Substitution treatment for opioid addicts in Germany. Harm Reduction Journal. 2007 February 2;4:5.
- Robertson JR, Raab GM, Bruce M, McKenzie JS, Storkey HR, Salter A. Addressing the efficacy of dihydrocodeine versus methadone as an alternative maintenance treatment for opiate dependence: A randomized controlled trial. Addiction. 2006 December;101(12):1752-9.